Procter & Gamble (PGHL) | Stock Overview & Key Data
Procter & Gamble Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹7,500.00 on February 8, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2024
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Procter & Gamble
PGHL
|
86.41B Mid-cap | 0.44% | 17.48% | 27.00% | 9.90% | 8.81% | 7.82% | 23.28% | 7.21% | 805.06% | 944.18% | 1,263.48% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | 1.34% | -2.25% | 8.85% | 4.11% | 4.17% | -0.43% | 85.44% | 58.15% | 496.33% | 1,610.60% | 10,946.76% |
|
Piramal Pharma
PPLPHARMA
|
199.68B Mid-cap | 1.12% | -4.39% | 20.53% | -2.62% | -1.58% | -18.17% | 77.37% | -2.17% | -2.17% | -2.17% | -2.17% |
|
Eris Lifesciences
ERIS
|
193.36B Mid-cap | 1.41% | 0.98% | 5.69% | -12.73% | -7.79% | -21.75% | 112.96% | 97.43% | 133.52% | 133.52% | 133.52% |
|
Neuland Laboratories
NEULANDLAB
|
184.81B Mid-cap | 0.54% | 2.81% | 39.46% | 3.75% | 13.25% | 30.36% | 489.12% | 756.32% | 2,077.38% | 16,439.72% | 20,028.75% |
Ownership & Short Interest
Calculate Your Procter & Gamble Investment Returns
Long-Term Investment Performance Analysis
Procter & Gamble stock price in Jul 2016 was ₹703.60, A ₹1,000.00 lump sum investment in Procter & Gamble made 9 years ago would be worth approximately ₹8,849.49 today, representing a exceptional return of 784.95%. This translates to an annualized return (CAGR) of 24.67%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is PGHL's 52-week high and low?
- In the last 52 weeks, Procter & Gamble reached a high of ₹6,739.00 (on August 29, 2025) and a low of ₹4,707.00 (on April 6, 2026).
- What is the market cap and P/E ratio for PGHL?
- Curious about Procter & Gamble's size and valuation? Its market capitalization stands at 86.41B. When it comes to valuation, the P/E ratio (trailing twelve months) is 36.48, and the forward P/E (looking ahead) is 27.46.
- Does PGHL pay dividends? If so, what's the yield?
- Yes, Procter & Gamble is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 5.20%, and the company has paid an average of ₹213.33 per share annually over the past 3 years.
- Who are Procter & Gamble's main competitors or similar companies to consider before investing?
When looking at Procter & Gamble, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.10% 82.23% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic -0.43% 85.44% Piramal Pharma
PPLPHARMA199.68B Healthcare Drug Manufacturers - Specialty & Generic -18.17% 77.37% Eris Lifesciences
ERIS193.36B Healthcare Drug Manufacturers - Specialty & Generic -21.75% 112.96% Neuland Laboratories
NEULANDLAB184.81B Healthcare Drug Manufacturers - Specialty & Generic 30.36% 489.12% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Procter & Gamble Health Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Procter & Gamble's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 37.34%, the Debt to Equity ratio from the most recent quarter is 1.00, and its Gross Profit Margin stands at 70.63%.
- What is the recent revenue and earnings growth for PGHL?
- Looking at Procter & Gamble's growth, its revenue over the trailing twelve months (TTM) was INR13B. Compared to the same quarter last year (YoY), quarterly revenue grew by 20.70%, and quarterly earnings saw a YoY growth of -14.60%.
- How much of PGHL stock is held by insiders and institutions?
- Wondering who owns Procter & Gamble stock? Company insiders (like executives and directors) hold about 52.20% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 15.99%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.